Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


21.08.2018

1 Clin Res Hepatol Gastroenterol
4 Gastroenterology
5 J Gastroenterol Hepatol
3 J Hepatol
2 Lancet Gastroenterol Hepatol
1 PLoS One
4 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Clin Res Hepatol Gastroenterol

  1. WANG C, Huang Z, Huang X, Liu C, et al
    Surgical outcomes between patients with and without a cirrhotic liver undergoing laparoscopic liver resection: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2018 Aug 10. pii: S2210-7401(18)30120.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. ASHHAB AA, Singh D, Debes JD
    A Rare Cause of a Left Abdominal Liver Mass.
    Gastroenterology. 2018;155:e12-e13.
    PubMed     Text format    

  3. THEVENOT T, Weil D, Di Martino V
    What is the true relationship between spontaneous portosystemic shunts and portopulmonary hypertension in cirrhotic patients?
    Gastroenterology. 2018 Aug 14. pii: S0016-5085(18)34878.
    PubMed     Text format    

  4. VILAR-GOMEZ E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, et al
    Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Gastroenterology. 2018;155:443-457.
    PubMed     Text format     Abstract available

  5. AJMERA V, Park CC, Caussy C, Singh S, et al
    Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2018;155:307-310.
    PubMed     Text format     Abstract available


    J Gastroenterol Hepatol

  6. ADINOLFI LE, Nevola R, Guerrera B, D'Alterio G, et al
    Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    J Gastroenterol Hepatol. 2018;33:1379-1382.
    PubMed     Text format     Abstract available

  7. KIM NH, Lee T, Cho YK, Kim BI, et al
    Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
    J Gastroenterol Hepatol. 2018 Jan 3. doi: 10.1111/jgh.14083.
    PubMed     Text format     Abstract available

  8. YEH CS, Hsu CW, Liang KH, Chen YC, et al
    Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation.
    J Gastroenterol Hepatol. 2018;33:1530-1537.
    PubMed     Text format     Abstract available

  9. WU SC, Chen WT, Muo CH, Hsu CY, et al
    A comparative study of subsequent liver cirrhosis risk in non- helicobacter pylori infected peptic ulcer patients with and without vagotomy: an Asian population cohort study.
    J Gastroenterol Hepatol. 2018 Aug 12. doi: 10.1111/jgh.14440.
    PubMed     Text format     Abstract available

  10. CHOE WH, Kim H, Lee SY, Choi YM, et al
    Three types of preS1 start codon deletion variants in the natural course of chronic hepatitis B infection.
    J Gastroenterol Hepatol. 2018;33:1370-1378.
    PubMed     Text format     Abstract available


    J Hepatol

  11. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available

  12. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    PubMed     Text format     Abstract available

  13. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  14. SANYAL AJ
    The fibrosis benefit index for assessment of therapeutic benefit in non-alcoholic steatohepatitis.
    Lancet Gastroenterol Hepatol. 2017;2:241-243.
    PubMed     Text format    

  15. VERNA EC
    Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Lancet Gastroenterol Hepatol. 2017;2:211-223.
    PubMed     Text format     Abstract available


    PLoS One

  16. PEISELER M, Reiners D, Pinnschmidt HO, Sebode M, et al
    Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.
    PLoS One. 2018;13:e0202686.
    PubMed     Text format     Abstract available


    Transplant Proc

  17. MUCENIC M, Bandeira de Mello Brandao A, Marroni CA, Medeiros Fleck A Jr., et al
    Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
    Transplant Proc. 2018;50:769-771.
    PubMed     Text format     Abstract available

  18. ROQUE L, Sankarankutty AK, Silva OC Jr., Mente ED, et al
    Evaluation of Lung Function in Liver Transplant Candidates.
    Transplant Proc. 2018;50:762-765.
    PubMed     Text format     Abstract available

  19. MARTINO RB, Waisberg DR, Dias APM, Inoue VBS, et al
    Stratifying Mortality in a Model for End-Stage Liver Disease Waiting List: A Brazilian Single-Center Study.
    Transplant Proc. 2018;50:758-761.
    PubMed     Text format     Abstract available

  20. OLMEDO-MARTIN RV, Amo-Trillo V, Gonzalez-Grande R, Tenorio-Gonzalez E, et al
    Efficacy and Safety of Anti-TNF-alpha Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series.
    Transplant Proc. 2018;50:619-622.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: